# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Duke Kahanamoku (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML050-SYN
- Date: 2026-03-16
- Fictional facility: St. Posthumous Health Center
- Fictional author: Kawika Lindgren-Morrison, MD
- Calendar frame: modern shifted

## What we are working on

- He wants to get back in the ocean, to swim and surf again **S**
- He wants to keep working as sheriff **S**
- He wants his ʻohana involved as he chooses and his own ways of healing respected **S**

## Your goals

- Euvolemia: no ankle swelling or orthopnea, with a steady dry weight. Target: 2026-04-27. Recorded outcome: Dry weight about 93 kg; no edema or orthopnea; furosemide reduced to 20 mg. **S**
- All four guideline-directed medicines at the highest doses he tolerates within three months. Target: 2026-09-28. Recorded outcome: All four classes started within two weeks of diagnosis; carvedilol 12.5 mg twice daily, empagliflozin and spironolactone at their doses; sacubitril-valsartan stayed at the starting dose for five months after a missed titration step and was raised at six months. **S**
- KCCQ-12 at least 20 points higher and NYHA class I to II within six months. Target: 2026-09-28. Recorded outcome: KCCQ-12 38 to 80; NYHA class I to II. **S**
- Back in the ocean safely, swimming in calm water with a companion. Target: 2026-09-28. Recorded outcome: Swimming three mornings a week in calm water inside the reef with a friend, after cardiac rehabilitation. **S**
- LDL cholesterol below 70 mg/dL. Target: 2026-04-27. Recorded outcome: LDL 62 mg/dL on atorvastatin 80 mg. **S**

## What we agreed to do

- Culturally safe care: address him as Mr. Kahanamoku, as he asked; take time; explain each test and medicine plainly; involve his ʻohana as he chooses while he makes the decisions. Guideline: Potentially Preventable Hospitalizations for Congestive Heart Failure Among Asian Americans and Pacific Islanders in Hawaiʻi (2015); Ke Ola Mamo: a Native Hawaiian Health Care System serving Oʻahu (medical care, lomilomi and community health workers) (2026) **S**
- Heart failure cardiology consultation on the day of the two-week visit, with an echocardiogram, to confirm the diagnosis and its cause and to plan guideline-directed medical therapy, ischemic evaluation and device decisions. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction (2024); CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026) **S**
- Furosemide 40 mg every morning for congestion, with a daily weight and a written plan; metabolic panel and magnesium in one to two weeks; lower the dose when he is dry. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026) **S**
- Baseline tests: ECG, chest X-ray, NT-proBNP, metabolic panel and magnesium, blood count, iron studies, TSH, hemoglobin A1c, lipids and ALT; echocardiogram at the two-week visit. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026) **S**
- Atorvastatin raised from 40 to 80 mg for LDL 92 mg/dL; lipid panel in four to twelve weeks; goal below 70 mg/dL. Guideline: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026) **S**
- Sodium: less salted and dried fish, shoyu and salty party food, using the foods he already eats; no routine fluid restriction; daily weights. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022) **S**
- Vaccinations: pneumococcal, influenza, COVID-19 and RSV as due, because heart disease raises the risk of severe respiratory infection. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); Adult Immunization Schedule by Age (2026) **S**
- Native Hawaiian healing alongside clinic care, if he wishes: lomilomi through Ke Ola Mamo, a Native Hawaiian Health Care System; he will tell the clinic before using any plant medicine so that interactions can be checked; the clinic asks nothing further about his practices. Guideline: Ke Ola Mamo: a Native Hawaiian Health Care System serving Oʻahu (medical care, lomilomi and community health workers) (2026) **S**
- Guideline-directed medical therapy: stop lisinopril and start sacubitril-valsartan 24/26 mg twice daily 36 hours after the last dose; change metoprolol tartrate to carvedilol 3.125 mg twice daily; empagliflozin 10 mg daily; add spironolactone when potassium and kidney function allow; raise one medicine every two weeks toward target doses, with a metabolic panel one to two weeks after each change. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction (2024); CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026) **S**
- Intravenous ferric carboxymaltose 750 mg at the two-week visit and again two weeks later, for iron deficiency in heart failure with reduced ejection fraction; iron studies again at about six months. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026) **S**
- Invasive coronary angiography within two weeks to define the coronary disease and whether revascularization could help. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023) **S**
- Defibrillator decision: repeat echocardiogram after at least 90 days of optimized therapy; a primary-prevention ICD if the ejection fraction stays at 35% or below with NYHA class II to III. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (2017); CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026) **S**
- Sick-day rules: on days of vomiting, diarrhea or not drinking, hold empagliflozin, furosemide, spironolactone and sacubitril-valsartan, keep carvedilol if blood pressure allows, drink small amounts often, and restart when eating and drinking normally for a day; a written card. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction (2024) **S**
- Cardiac rehabilitation for heart failure, 36 sessions, adapted to an ocean athlete: pool swimming in the program, then calm water inside the reef with a companion and near a lifeguard, no breath-hold diving, no big surf until cleared, water through the morning, and out of the water at once for chest pain, lightheadedness or unusual breathlessness. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026) **S**
- Laboratory tests drawn at the clinic on the day of each medicine change or by the clinic's nurse at home, with nurse calls to titrate doses between visits. Guideline: 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction (2024); CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026) **S**

## Follow-up

- 2026-03-16: Establishing care for six weeks of breathlessness, ankle swelling and tiredness five years after a heart attack: examination, ECG, chest X-ray, NT-proBNP and laboratory tests, a diuretic, and the plan for an echocardiogram **S**
- 2026-03-30: Two-week review: echocardiogram, heart failure cardiology consultation the same day, the diagnosis, and guideline-directed medicines **S**
- 2026-04-13: Two-week review after sacubitril-valsartan, carvedilol and empagliflozin: kidney function, potassium, angiography result and the next medicine **S**
- 2026-04-27: Two-week review, five days after the sick visit: kidney function and potassium, medicine doses, lipids, and cardiac rehabilitation adapted to the ocean **S**
- 2026-09-14: Subsequent annual wellness visit **S**
- 2026-09-28: Six-month review: repeat echocardiogram after more than 90 days of therapy, the defibrillator decision, iron, the delayed titration step, and plans for the year **S**

This teaching document does not replace care from a qualified clinician.
